Key result
Current literature provides no convincing evidence of an increased risk of clinically significant cardiac valvulopathy in patients treated with dopamine agonists for hyperprolactinemia.
Why the study?
Does dopamine agonist therapy increase the risk of valvular heart disease in patients with hyperprolactinemia?
Does dopamine agonist therapy increase the risk of valvular heart disease in patients with hyperprolactinemia?
Dopamine agonists used at lower doses for hyperprolactinemia do not appear to carry the same high risk of fibrotic valvular heart disease as the higher doses used for Parkinson's disease.
Supports low-dose dopamine agonist use in hyperprolactinemia without routine valve monitoring; leaves open need for prospective confirmation.
A number of publications of the 1990s found an association between the development of disease of the heart valves and the use of dopamine agonists in patients receiving treatment for Parkinson’s disease. Therefore, it became necessary to investigate the possible risks of valve disease in patients with hyperprolactinemia receiving treatment with dopamine agonists, in order to improve the recommendations.
No takes yet. Share an insight, caveat, or question.
Давыдова et al. (2012) conducted a review in Hyperprolactinemia. Dopamine agonists vs. No dopamine agonist therapy was evaluated. Current literature provides no convincing evidence of an increased risk of clinically significant cardiac valvulopathy in patients treated with dopamine agonists for hyperprolactinemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: